Regents of the University of Minnesota;St. Jude Children's Research Hospital, Inc.
发明人:
Bruce R. Blazar,Brent Koehn,Peter J. Murray,Jenny P.Y. Ting,Robert Zeiser,Jeff S. Miller
申请号：
US15747902
公开号：
US20180214483A1
申请日:
2016.08.05
申请国别(地区):
US
年份:
2018
代理人:
摘要：
In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
